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Abstract
Background: Tumor targeting is of high clinical and biological relevance, and major efforts have been made to
develop molecular imaging technologies for visualization of the disease markers in tissue. Of particular interest is
apoptosis which has a profound role within tumor development and has significant effect on cancer malignancy.
Methods: Herein, we report on targeting of phosphatidylserine-exposing cells within live tumor allograft models
using a synthetic near infrared zinc(II)-dipicolylamine probe. Visualization of the probe biodistribution is performed
with whole body multispectral optoacoustic tomography (MSOT) system and subsequently compared to results
attained by planar and tomographic fluorescence imaging systems.
Results: Compared to whole body optical visualization methods, MSOT attains remarkably better imaging capacity
by delivering high-resolution scans of both disease morphology and molecular function in real time. Enhanced
resolution of MSOT clearly showed that the probe mainly localizes in the vessels surrounding the tumor,
suggesting that its tumor selectivity is gained by targeting the phosphatidylserine exposed on the surface of tumor
vessels.
Conclusions: The current study demonstrates the high potential of MSOT to broadly impact the fields of tumor
diagnostics and preclinical drug development.
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Background
A versatile pool of optical reporter agents and imaging
methods for enhancement and probing of anatomical
features and molecular function of tumors has been
recently developed [1,2]. The contrast carriers reach
from fluorochromes [3] and other organic dyes to quan-
tum dots [4] and several forms of nanoparticles [5,6]
with a large selection of accumulation, targeting and
activation mechanisms [7,8]. It has been long realized
that apoptosis plays a profound role within tumor devel-
opment and has significant effect on cancer malignancy
[9]. Therefore, many anticancer treatment strategies are
based on the induction of apoptosis in tumors [10], and
early monitoring of such treatment success is of great
interest within preclinical drug development. Even
though optical molecular markers of apoptosis are
generally available [11,12], their in vivo visualization is
challenging due to intensive light scattering in living tis-
sues. Some earlier attempts to specifically image apopto-
tic responses in whole living animals using fluorescence
molecular tomography attained generally low spatial
resolution and imaging speed [13,14]. As a result, ques-
tions related to the exact probe localization (e.g., necro-
tic foci within the tumors versus surface of the tumor
blood vessels) cannot be answered using those methods.
More recently, multispectral optoacoustic tomography
(MSOT) has been emerging as a promising tool for
high-resolution volumetric imaging of optical contrast in
tissues [15], capable of visualizing tissue chromophores
with ultrasonic resolution independent from light scat-
tering [16]. The use of multispectral methods allows to
efficiently resolve extrinsic optical agents, such as fluor-
ochromes and fluorescent proteins [17,18]. Optoacoustic
imaging correspondingly offers important advantages in
small animal imaging, including the use of non-ionizing
radiation, the versatile sensing of chromophoric
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good spatial resolution and, in analogy to ultrasound
imaging, real-time operation [19-21].
Recently, a novel optical probe, comprised of a syn-
thetic zinc(II)-dipicolylamine complex appended to a
near-IR (NIR) carbocyanine fluorophore (subsequently
called PSS-794), has been shown to selectively target
anionic membrane-bound phosphatidylserine (PS)
exposed by dead and dying cells within xenograft
tumors in rat and mouse models [22]. Usually restricted
to the inner leaflet of the plasma membrane, phosphati-
dylserine is selectively exposed as an early event during
cell apoptosis, which is a crucial mechanism of cell
number control in various physiological and pathological
events [23]. Herein, we investigate whether PSS-794 can
be used to image tumors in vivo with high resolution
using MSOT.
Methods
Multispectral optoacoustic tomography system
A real-time MSOT scanner, similar to the one described
by Razansky et al. [21], was utilized in this study (Figure
1). Briefly, it is based on an excitation source from a
tuneable (680-950 nm) optical parametric oscillator laser
(Phocus, Opotek Inc., Carlsbad, CA, USA) delivering <
10-ns duration pulses with repetition frequency of 10
Hz. The laser beam is guided into a silica fused-end
fiber bundle (PowerLightGuide, CeramOptec GmbH,
Bonn, Germany) consisting of 630 fibers partitioned into
ten arms, thus, creating a ring-shaped illumination pat-
tern of approximately 8-mm width upon the surface of
the animal. The beam was sufficiently broadened to
keep the laser pulse fluence on the surface of imaged
objects under 20 mJ/cm
2 in order to meet the laser
safety standards. Signal collection is based on a custom-
made 64-element focused transducer array (Imasonic
SaS, Voray, France) covering a solid angle of 172°
around the imaged object, while the detection plane
coincided with the center of the illumination ring. The
individual detection elements are manufactured using
piezocomposite technology with central frequency of 5
MHz, bandwidth of more than 50%, and sensitivity of
approximately 18 μV/Pa and are shaped to create a
cylindrical focus at 40 mm. According to ultrasonic dif-
fraction limit and focal width at the central frequency,
the effective spatial resolution of the system is estimated
at 150 μm (in-plane) and 800 μm (elevational). The
detected signals are digitized at 60 megasamples per sec-
ond frequency by eight multichannel analog to digital
converters (PXI5105, National Instruments, Austin, TX,
USA) with noise floor of approximately 3.8 nV/
√
Hz.
To facilitate in vivo measurements, the animals were
wrapped by a water-impenetrable transparent membrane
that averts animal contact with water inside the imaging
chamber. A linear stage (NRT150, Thorlabs GmbH,
Karlsfeld, Germany) allows linear translation of the ani-
mal holder in the axial z direction for the acquisition of
three-dimensional data sets.
Animal imaging
All procedures involving animals and their care were
conducted in full agreement with the institutional guide-
lines, complying with national and international laws
and regulations. For imaging, four female 8-week old
athymic CD-1 nude mice containing 4T1 tumor allo-
grafts were used. The tumors were obtained by injecting
0.8 × 10
5 4T1 cells subcutaneously into the mouse’s
neck where they were allowed to grow for 7 days, reach-
ing a diameter of 0.4-0.5 cm. The PSS-794 imaging
probe was prepared as previously reported [24]. The
first two tumor-carrying mice were injected intrave-
nously via the tail vein 24 h prior to imaging with 6
mg/kg (100 nmoles) and 3 mg/kg (50 nmol) of the
probe, respectively. A third mouse was injected 3 h
prior imaging with probe amount of 3 mg/kg (50 nmol).
Figure 1 MSOT system.( a) Schematic representation of the MSOT
system. A curved array of wideband and cylindrically focused
ultrasound transducers enable parallel data acquisition. Optical fibers
are used to homogeneously illuminate the object. A special animal
holder with a transparent plastic membrane is used for animal
positioning and protects the animal from direct contact with water.
(b) Picture of a mouse during a scan in the MSOT system showing
key components of the system.
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(50 nmol) of indocyanine green (ICG), a non-targeted
dye having spectral characteristics similar to PSS-794 in
the near-infrared, 3 h prior imaging [21]. The mice were
anesthetized with a mixture of ketamine and xylazine,
and were placed in supine position in the animal holder.
Cross-sectional multispectral optoacoustic image data-
sets were acquired through the tumor at six different
wavelengths in the NIR window (700, 740, 760, 780,
800, and 900 nm). For quantitative readings, the inter-
wavelength laser energy variations were corrected for by
normalizing the data by power meter readings (Field-
MaxII-TOP, Coherent GmbH, Dieburg, Germany).
Image reconstruction and analysis
Reconstruction of single-wavelength optoacoustic images
was done with interpolated matrix model inversion
method [25]. Prior to inversion, the raw optoacoustic
signals were bandpass-filtered between 50 kHz and 7
MHz, and deconvolved with the combined electrical
impulse response of the ultrasonic detectors and the
acquisition system [26]. For inversion of the forward
matrix, the iterative PLSQR algorithm has been used
[27]. To selectively detect the biodistribution of the
probe over intrinsic tissue absorption background, mul-
tispectral un-mixing by independent component analysis
(ICA) [28] was applied.
This technique is based on the assumption that the
source components of the mixed multispectral dataset
are statistically independent. In order to identify these
source components, the algorithm seeks a transforma-
tion of the dependant multispectral dataset into a set of
independent variables which is accomplished by maxi-
mizing their non-Gaussianity because, according to the
central limit-theorem, statistical independent variables
are less Gaussian than their mixed dependent counter-
parts. The measured absorption spectra of the probe
and oxygenized and deoxygenized blood were fed to the
algorithm as a starting point for a guided un-mixing.
The probe component was identified by comparing the
resulting spectra from the un-mixing algorithm with the
measured probe spectra. In contrast to other methods
based on least-square un-mixing, which try to fit an a
priori known spectra to the data, the ICA algorithm has
more degrees of freedom which reduces the cross talk
and leads to generally better performance.
Cross-validation with fluorescence measurements
For validation purposes, one mouse was also imaged ex
vivo with a newly developed 360° free-space FMT-XCT
system which combines fluorescence molecular tomo-
graphy (FMT) with small animal X-ray CT (XCT) into a
hybrid imaging device [29]. The system was capable of
simultaneous three-dimensional visualization of small
animal anatomy and biodistribution of fluorescent
probes in vivo. For volumetric FMT reconstructions, 12
angular projections distributed over full 360° range were
acquired close to the excitation and emission wave-
lengths of PSS-794. Following the FMT-XCT measure-
ment, the euthanized mice were cooled to -80°C. For
further verification of the in vivo MSOT and FMT
images, cross-sectional color photographs (RGB) and
fluorescence images were also obtained using a cryo-
tome supplemented by a home-built multispectral epi-
fluorescence system [30]. The system consisted of a
white light source and a sensitive CCD camera with
motorized filter wheels for selection of the excitation
(740 nm, 40 nm bandpass filter) and emission (785 nm
longpass filter) wavelengths.
Histology
After cryo-slicing, selective tissue samples in the tumor
area were used for histological validation for highly spe-
cific detection of apoptosis using commercially available
annexin V antibody (Abcam PLC, Cambridge, United
Kingdom). The appearance of PS residues (normally
hidden within the plasma membrane) on the surface of
the cell is an early parameter of apoptosis, which can
also be used to detect and measure apoptosis. During
apoptosis, PS is translocated from the cytoplasmic face
of the plasma membrane to the cell surface. Annexin V
has a strong Ca2+-dependent affinity for PS and, there-
fore, can be used as a probe for detecting apoptosis.
Results
Figure 2 depicts the molar extinction coefficient of the
targeted PSS-794 probe in 35 mg/ml albumin acquired
using a fiber optic spectrophotometer (USB2000, Ocean
Figure 2 Molar extinction coefficient of PSS-794.I n3 5m g / m l
albumin along with extinction spectra of oxygenized and
deoxygenized hemoglobin.
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oxygenized and deoxygenized hemoglobin. The spec-
trum of PSS-794 has a characteristic shape with an
absorption maximum at 810 nm close to the isosbestic
point of blood. It, thus, differs significantly from the
major background tissue absorbers, making it well sui-
ted for multispectral optoacoustic detection with high
sensitivity.
Figure 3a, d show the spectrally unmixed MSOT sig-
nals from the two mice imaged in vivo 24 h after injec-
t i o n s .T h es i n g l ew a v e l e n g t ho p t o a c o u s t i ci m a g e s
acquired at 900 nm are shown in gray scale, while the
spectrally unmixed MSOT signals are superimposed in
color. A transparency threshold of 65% was applied to
the unmixed data when superimposed to the single
wavelength background image. The boundary of the
tumor is delineated in yellow. Figure 3h shows the result
from the mouse imaged 3 h after injection, and Figure
3k the result for the mouse injected with ICG also
imaged 3 h after injection. The PSS-794 signal is visible
in all the three cases, whereas signal from ICG is not
detectable. Apparently, analysis of the high-resolution
MSOT images clearly shows that the PSS-794 probe
mainly accumulates in the blood vessels surrounding the
tumors, while no infiltration of the probe into the tumor
mass occurs.
On the other hand, reconstruction of the subsequent
ex vivo FMT measurement, shown in Figure 4c, gener-
ally confirms the fact that the probe specifically accumu-
lated around the tumor areas. Yet, due to the lower
resolution of the method, it is difficult to determine
whether the fluorescence signal is originating only from
the vasculature or from within the tumor parenchyma.
The exact origin of the fluorescence signal is also not
recognizable from the poorly resolved transillumination
fluorescence image (Figure 4d). The results of the vali-
dation cryo-slicing and epi-fluorescence studies, made
on euthanized mice, are shown in Figure 3b, e, i, l. The
color pictures of the cryo-sliced mouse in Figure 3c, f, j,
g shows the actual location of the tumor mass, which
can also be readily delineated on the single-wavelength
optoacoustic images. Observation of the brown spots in
Figure 3 Imaging of targeted apoptotic marker (PSS-794) in 4 T1 tumor-bearing mice. In the first column, the MSOT images are shown.
Images (a) and (d) show superposition of a single-wavelength (anatomical) optoacoustic image (in gray scale) and the unmixed component
corresponding to the PSS-794 signal in color for the two mice imaged 24 h after injection. (h) shows the unmixed PSS-794 signal for the mouse
imaged 3 h post injection, and (k) the ICG signal also imaged 3 h post injection. The second column shows the corresponding epi-fluorescence
images of cryo-slices through the tumor. Color photograph of cryo-slices are shown in the third column. The tumor area is delineated in yellow.
Figure 4 Comparison between optical imaging and MSOT.
Image (a) shows the MSOT image, and (b) the corresponding epi-
fluoresence image. An FMT-XCT reconstruction is shown in (c) and a
planar transillumination image in (d)
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relatively small amount of apoptotic tissue exists in the
tumor.
In summary, both the in vivo MSOT and the ex vivo
epi-fluorescence images clearly reveal that the fluores-
cence signal of the PSS-794 probe is localized in the
blood vessels surrounding the tumor. This observation
agrees well with literature which shows that, once there
is only a small amount of apoptotic tissue in this tumor
cell line, PS-targeting probes will be only observed in
the tumor blood vessels [31].
Discussion
Previous studies have shown that the fluorescent PS-tar-
geting probe, PSS-794, can be used to optically image
apoptotic/necrotic tissues often found inside tumors
[22]. Here, it is demonstrated for the first time that
PSS-794 also allows imaging of 4T1 tumor allografts
without an actual infiltration of the probe into the
tumor mass. In our experiments, lack of depth resolu-
tion of planar fluorescence imaging might have mista-
kenly led to the conclusion that PSS-794 is concentrated
in the tumor mass. Even the use of three-dimensional
optical tomography (FMT) has not attained the suffi-
cient spatial resolution that would determine the precise
location of the probe. In contrast, the much higher reso-
lution of the MSOT revealed accumulation of the PSS-
794 in the blood vessels surrounding the tumor area
and clearly showed no infiltration into the tumor mass.
This lack of extravasation has been also confirmed by
the epi-fluorescence images made on the cryo-sliced
mouse. This suggests that the vasculature of the tumor
was not leaky.
The lack of extravasation is not surprising in this case
since both probes are known to associate with serum
proteins, and it is hard for the large protein/dye com-
plex to leak from the neovasculature, especially if there
is a high interstitial pressure in the tumor [32]. On the
other hand, since the unspecific ICG dye is not detected
in the tumor area while PSS-794 stays in the tumor ves-
sels much longer, we conclude that the PSS-794 is still
targeting a certain biomarker most likely the PS exposed
on vessel walls of the neovasculature [33,34]. There is
evidence that 20-40% of the blood vessel surfaces in all
tumors, and metastases that are larger than 1 mm
expose PS even though these endothelial cells are vital
and not apoptotic [35]. Moreover, it normally takes 6-24
h to exert the enhanced permeability and retention
(EPR) effect [36]. Thus, the strong retainment of PSS-
794 at the tumor by 3 h (Figure 3h) cannot be explained
either by the EPR. This is because, if the tumors were
leaky, both PSS-794 and ICG should have been observed
within the tumor parenchyma.
The PS-binding antibody Bavituximab
® (a human chi-
meric version of the murine monoclonal IgG3 antibody,
3G4) is especially effective at targeting this class of
exposed PS, and it induces impressive antitumor activity
in a wide array of tumors with no evidence of toxicity
[37,38]. This raises the idea that zinc(II)-dipicolylmine
complexes may have value as near-universal targeting
agents for imaging and treatment of tumors; however,
more studies are needed to test this interesting hypoth-
esis. The current study showcases the power of MSOT
to uncover new high resolution information about the
precise location of imaging probes within sites of
disease.
Conclusions
In conclusion, we used MSOT to accurately detect the
targeted PSS-794 probe in vivo over strong background
absorption of blood with spatial resolution on the order
of 150 μm, attaining unprecedented image quality for
deep-tissue imaging of optical contrast. The enhanced
resolution of the MSOT clearly showed that the probe
mainly localizes in the vessels surrounding the tumor,
suggesting that the probe gains its tumor selectivity by
targeting the PS that is exposed on the surface of the
tumor blood vessels. The MSOT results further corre-
lated well with cryo-slices and epi-fluorescence images
of ex vivo specimens. Overall, this study demonstrates
the high potential of MSOT to broadly impact the fields
of tumor diagnostics and preclinical drug development.
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Figure 5 Representative histological slice of the tumor mass.
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